All eyes on Olumiant a Jak1/Jak2 Inhibitor with results due this month for Covid-19, highly anticipated results and could be a game changer for Sareum as SDC-1801 may be more effective and/or be better tolerated, Lilly’s Olumiant has boxed safety warnings alerting to an elevated risk of serious infections, tuberculosis, lymphoma, or other malignancies and thrombosis: https://investor.lilly.com/news-releases/news-release-details/lilly-begins-phase-3-clinical-trial-baricitinib-hospitalized
Good resource for current/planned trials Inc preclinical in Covid-19: https://covid-19tracker.milkeninstitute.org Sareum to join the list who knows maybe!!!
In other news Sanofi’s Kevzara Phase 3 trial in severe and critically ill COVID-19 patients failed to meet its primary & secondary endpoints: https://www.sanofi.com/en/media-room/press-releases/2020/2020-09-01-07-00-00
SDC-1802 Updated 28 Aug 2020 - Precursor T-cell lymphoblastic leukaemia-lymphoma
https://adisinsight.springer.com/drugs/800046612
SDC-1801 Last update - Available for licensing as of 15 Jun 2020.
https://adisinsight.springer.com/drugs/800058961
Late preclinical License deal for our TYK2’s bring it on clocks ticking GLA
Andy my previous comment was to suggest that it would qualify for Orpan Drug Designation in Pediatric Osteosarcoma / Clear Unmet Medical Need / FDA Grant Funding Available / Fast Tracked to Market. Sierra & Merck will be fully aware of the data and potential here not forgetting Merck's M4344 Inhibitor was also tested recently in combination with SAR737 Interesting times GLA
Merck's BET Inhibitor & CHK1 SRA737
Enjoy Full Release
Published 26th August 2020
Article: https://www.mdpi.com/2072-6694/12/9/2426
Video: https://www.mdpi.com/video_load/86271bcf2a5f64d9f52a9b600a323bb2/mp4
PDF download: https://www.mdpi.com/2072-6694/12/9/2426/pdf
TYK2 Updates on preclinical (IND-enabling) tox studies (H2 2020)
TYK2 Journal paper on preclinical studies (SDC-1802 vs. solid tumours) (H2 2020)
TYK2 SDC-1801 Potential IND Submission (H2 2020)
TYK2 Potential for preclinical licence deal (Anytime $$$$$$$$$$)
TYK2 Covid-19 potential UKRI grant approval (October 2020)
TYK2 Further grant applications for Covid-19 research (H2 2020)
SRA737 Clarity on future development funding & plans (Anytime)
SRA737 Final Data readouts from ongoing and completed clinical studies (H2 2020)
SRA737 Potential milestone payments*
FLT3 Updates on IND-enabling tox studies (Anytime -4 months)
FLT3 Potential milestone payments+ (Anytime -4 months)
Results of Phase 3 Olumiant in Covid-19 (September 2020) (Closely watched, Highly promising)
Results of Phase 3 Jakafi in Covid-19 (October 2020)
Final Phase 3 data BMS-986165 psoriasis (H2 2020)
Phase 2 data on Brepocitinib UC and Chron's (H2 2020)
I imagine some haven’t seen this or didnt bookmark it; data cut off was up to May 3rd 2019 /
http://investor.sierraoncology.com/download/ASCO+SRA737+Analyst+Call+Presentation_final.pdf
Enjoy the read and have a great weekend
The novel ATR inhibitor M4344 and CHK1 inhibitor SRA737 overcome chemoresistance in SLFN11-negative cells in combination treatment with DNA-damaging agents
https://cancerres.aacrjournals.org/content/80/16_Supplement/LB-121
Thoth didnt realise it was one of Merck's had never heard of it before:
Acquisition Expands Merck’s Oncology Portfolio with Novel Oral BET Inhibitor, OTX015
https://www.endeavourvision.com/merck-acquires-oncoethix-a-privately-held-oncology-company-developing-novel-bet-inhibitors-for-hematological-and-solid-cancers/
BET and CHK1 in aggressive pediatric osteosarcoma
Once tumor volumes reached 100-150 mm3, mice were randomized and treated with four 5-day cycles of BETi/OTX-015 and/or CHK1i/SRA737. BETi+CHK1i significantly decreased TT2-77 growth, increased probability of survival, and was well tolerated.
https://cancerres.aacrjournals.org/content/80/16_Supplement/450
Forgot the link:
http://www.sierraoncology.com/wp-content/uploads/2020/08/JobDescription_DirectorofBusinessDevelopment-_20200814.pdf
Invester meet slide presentation available on the website for anyone who missed it
http://www.sareum.com/news/presentations/
Direct Link to Slide PDF presentation below:
http://www.sareum.com/files/9115/9767/8722/Sareum_Update_14_AUG_draft_vF.pdf
Bristol hopes to Tyk the psoriasis box
https://www.evaluate.com/vantage/articles/events/company-events/bristol-hopes-tyk-psoriasis-box
The important thing here is how fast they could get SRA737 commercialised which puts us in a whole new world, a clear unmet medical need!!! A registration intent study!!! Very good preliminary data, patients still on trial hold onto your hats when this news lands the rerate here will be massive without the Two TYK2’s and FLT3 Aurora. The coming months have every possibility of being transformational for Sar GLA.